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INTRODUCTION
Crohn disease (CD) is characterized for periods of ex-
acerbation that alternate with periods of remission (1). 
Even with the great advances on CD pathogenesis and 
available therapeutic options, most of the patients re-
quire an intestinal surgery during their lifetime (1,2).
Endoscopic recurrence (ER) is defined as the reappear-
ance of lesions after complete surgical resection. New 
lesions can recur in the anastomotic region within 
weeks to months of surgery, and after ileal resection, 
nearly 80% of the patients have new lesions in the neo-
terminal ileum within 1 year after resection (3,4). 
Endoscopic recurrence is determined by the presence of in-
flammation and ulceration and is categorized according to 
the Rutgeerts´ score (3). There is a gap between clinical recur-
rence and ER, and the severity of endoscopic lesions post-sur-
gery predict clinical relapse (3). Once clinical relapse interferes 
with the patient´s quality of life, it is essential to stratify the risk 
for post-surgery relapse (5). Therefore, an ileocolonoscopy 
evaluation within the first year after resection may be useful 
for stratifying patients at a high risk for clinical recurrence (3).
This study aimed to determine the rate of ER and to 
determine ER predictors in patients with CD at 6-12 
months after surgery.
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ABSTRACT
Background/Aims: Identifying predictors of endoscopic recurrence (ER) has become very important to guide 
the decision of postoperative strategy. This study aimed to determine the rate of endoscopic recurrence until 
12 months after ileocolic resection for Crohn disease (CD) in a cohort and identify its possible predictors.
Materials and Methods: We conducted a retrospective single-center study that included patients with CD 
who underwent ileocolic resection between 2003 and 2014. ER was defined according to the Rutgeerts’ score, 
defined as i2, i3, or i4 at ileocolonoscopy that was performed 6-12 months after surgery. The patients were 
classified into two groups according to the Rutgeerts´ score: non-ER (Rutgeerts i0/i1) and ER (Rutgeerts ≥i2). 
Multivariate logistic regression analysis was performed, including significant variables on univariable analysis, 
to identify ER predictors.
Results: Forty-two patients were included. The mean period of the first postoperative colonoscopy was 9 months, 
and ER was observed in 25 patients (59.5%). The perianal disease and shorter duration of CD were the only ER pre-
dictors (p=0.024; OR, 8.36; 95% CI, 1.329-52.642 and p=0.039; OR, 0.965; 95% CI, 0.933-0.998, respectively).
Conclusion: Endoscopic recurrence affects almost two-thirds of patients with CD after ileocolic resection, with 
perianal involvement and a shorter duration of disease being significant risk factors. These factors may indicate 
a more aggressive disease associated with rapid progression and support the need of intensive early treatment 
to improve patients’ outcomes.
Keywords: Crohn disease, endoscopy, surgery
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MATERIALS AND METHODS
We reviewed and analyzed the medical records of a cohort at 
a single center who underwent ileocolic resection for CD be-
tween January 2003 and December 2014. All data were col-
lected from the general electronic data system of the Hospital 
da Senhora da Oliveira, Guimarães, Portugal.
Patients with incomplete surgical resection and positive mar-
gins on the surgical specimen; who were scheduled for a fol-
low-up period of <1 year; who had previous history of stricture-
plasty, bowel or colonic resection, and perianal surgery; and 
who did not undergo colonoscopy within 1 year after surgery 
were excluded. The median time to the first ileocolonoscopy 
after surgery was determined.
Patients were classified into two groups according to the Rut-
geerts´ score (3): non-ER (Rutgeerts i0/i1) and ER (Rutgeerts 
≥i2). The potential risk factors for ER (≥i2) were analyzed and 
divided into four groups: factors related to the patient, disease, 
surgery, and pharmacological treatment.
Regarding the indication for surgery, patients were divided into 
two groups (6). Perforating indication was defined as acute free 
perforation, subacute perforation with an abscess, and chronic 
perforation fistula formation. Non-perforating indication was 
defined as intestinal obstruction, medical intractability, hemor-
rhage, and toxic dilation (6).
This study was conducted according to principles of the World 
Medical Association Declaration of Helsinki. Anonymous clini-
cal data were obtained after each patient agreed to the proce-
dure by providing written informed consent.
Statistical Analysis
Statistical analyses were performed using Statistical Package 
for Social Sciences version 20.0 (IBM Corp.; Armonk, NY, USA). A 
multivariate logistic regression analysis was performed that in-
cluded only factors that were significant on univariable analysis 
to identify factors associated with ER. Thus, p values of <0.05 
were considered to be statistically significant.
RESULTS
Seventy patients of our center underwent ileocolic resection. 
Complete medical records were obtained from 58 patients; 
however, only 42 patients met our inclusion criteria. Of these, 
50% were females and had a mean age of 29.2 years [interquar-
tile range (IQR), 21-34.8 years] at CD diagnosis. 
The first colonoscopy on follow-up was performed at an aver-
age of 9 months (IQR, 6-12 months) after surgery, and an over-
all ER was observed in 59.5% of patients (25 of 42); of those, 
52% of patients (13 of 25) had severe ER (≥i3) (Table 1).
Clinical observations and demographics of these patients and 
their medical therapy were comparable between the ER and 
non-ER groups (Table 2). None of these factors were associated 
with ER. The median age of the patients at the time of resection 
was 32.3 years (IQR, 23-41.3 years).
At the time of surgery, 25 patients (59.5%) had never 
smoked, 13 (31%) were current smokers, and 4 (9.5 %) were 
ex-smokers.
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Rutgeerts N (%)
i0 14 (33.3)
i1 3 (7.1)
i2 12 (28.6)
i3 8 (19)
i4 5 (11.9)
Table 1. Rutgeerts´ score
Variable ER Non-ER p
Gender   0.346
Female 11 10
Male 14 7
Family history of IBD 2 0 0.506
Age at surgery (years) 30.3±10.9 35.3±10.2 0.141 
(mean±SD)
Smoking   1
Never smoked 16 9 
Current smoker 8 5 0.331
Ex-smoker 1 3 
Preoperative medications   
Corticosteroids 13 6 0.353
Mesalamine 12 6 0.414
Azathioprine 11 8 1
Anti-TNF drugs 4 2 1
Postoperative medications   
Mesalamine 12 10 0.491
Azathioprine 19 12 0.733
Anti-TNF drugs 6 5 0.733
Start time of mesalamine 22.3±31.7 11.4±18.1 0.350 
after surgery (days)  
(mean±SD)
Start time of AZT  38.7±28.9 76.3±68.9 0.083 
after surgery (days)  
(mean±SD)
Start time of anti-TNF  49.8±36.7 44.4±17.2 0.769 
drugs after surgery  
(days) (mean±SD)
AZT: azathioprine; ER: endoscopic recurrence; IBD: inflammatory bowel disease; SD: 
standard deviation; TNF: tumor necrosis factor
Table 2. Factors related to the patient and to medical therapy
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Only 2 patients (4.8%) had a family history of inflammatory 
bowel disease.
The choice to initiate prophylactic therapy after surgery with 
azathioprine, anti-TNF drugs, or both in combination were 
based on the penetrating phenotype and other aggressive 
disease factors, such as perianal disease and age <40 years at 
diagnosis in 83.3% of patients (35 of 42). 
After surgery, 31 patients took azathioprine; of these, 19 
had ER (p=0.733). Eleven patients took anti-tumor necro-
sis factor (anti-TNF) drugs after surgery; of these, 6 had ER 
(p=0.733). Disease-related factors were compared between 
the two groups, as shown in Table 3. The median duration 
between CD diagnosis and surgery was 32 months (range, 
0-254 months).
According to the Montreal classification, the majority of our pa-
tients were A2 (78.6%). Regarding the disease location, 35.7% 
exhibited disease in the ileum (L1), 64.3% in the ileocolic, and 
none with only colon involvement. Patients mainly presented 
with penetrating behavior (L3) (69%), and 31% had stricturing 
disease (L2). None of the patients concomitantly presented 
with upper gastrointestinal tract involvement.
Of the 15 patients with perianal disease, 13 had ER on fol-
low-up (p=0.008). There was a higher incidence of ER in 
patients with a shorter duration of disease (13.9 vs. 59.2 
months, with ER and non-ER, respectively, p=0.019). Table 4 
shows surgery-related factors that were compared between 
the two groups.
Patients underwent ileocolic resection for strictures (33.3%), 
abscess and fistula (52.4%), and free perforation (14.3%). 
Among the 28 patients with perforating indications, 17 had ER; 
eight of the 14 patients with non-perforating indications had 
ER, without significant statistical difference between the two 
groups (p=0.824).
An urgent operation was performed in 18 patients (42.9%).
The mean length of the intestine resected was 37.1±20 cm, 
none with a large intestinal resection. We found no association 
with regard to the intestine length resected and ER (p=0.813).
The presence of wall granulomas was noted in 19 patients 
(45.2%), 12 in ER patients, and 7 in patients without ER 
(p=0.663). The granulomas of mesenteric lymph nodes were 
identified in 6 (14.3%) patients: 2 with ER and 4 without ER 
(p=0.202).
In the multivariate analysis, the perianal disease and shorter 
duration of CD remained the only ER predictors (p=0.024; 
OR, 8.36; 95% CI, 1.329-52.642 and p=0.039; OR. 0.965; 95% CI. 
0.933-0.998, respectively).
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 ER Non-ER p
Age at diagnosis   
A2 19 14 0.716
A3 6 3 
Disease location   
L1 10 5 0.482
L3 15 12 
Disease	behavior   
B2 8 5 0.859
B3 12 17 
Perianal disease 13 2 0.008
Disease Duration  13.9±17.7 59.2±70.4 0.019 
(months) (mean±SD)
ERS (mm/hour) 18.8±14.7 15.1±14.3 0.423 
(mean±SD)
CRP (mg/L) 8.8 ±16.5 7.2±13.1 0.727 
(mean±SD)
CRP: C reactive protein; ER: endoscopic recurrence; ERS: erythrocyte sedimentation rate; 
SD: standard deviation
Table 3. Disease related factors
 ER Non-ER p
Timing of surgery   
Elective 14 10 0.856
Urgent 11 7 
Indication   
Perforating 17 11 0.824
Non-perforating 8 6 
Surgical procedure   
Open 23 16 1
Laparoscopic 2 1 
Type of anastomosis   
Side to side 24 16 1
End to side 1 1 
Postoperative	complications 3 3 0.672
Intra-abdominal abscess 1 2 0.556
Anastomotic dehiscence 2 1 1
Extension of the specimen  37.7±16.1 36.2±25.2 0.813 
(cm) (mean±SD)
Granulomas in surgical  12 7 0.663 
specimen wall
Granulomas in mesenteric  2 4 0.202 
lymph nodes
ER: endoscopic recurrence; SD: standard deviation
Table 4. Surgery-related factors
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DISCUSSION
Crohn disease surgery is not curative because the disease often 
recurs in the remaining bowel (3). According to the European 
Crohn´s and Colitis Organisation consensus, the following fac-
tors have been shown to predict early postoperative recur-
rence in the majority of studies: smoking, prior intestinal sur-
gery, penetrating disease behavior, perianal involvement, and 
extended small bowel resection (>100 cm) (7).
Although they are, by consensus, risk factors for postopera-
tive recurrence, there are a disparity of results between several 
studies that may be explained by the ambiguous definition of 
disease recurrence and the type and number of predictors fac-
tors included. In fact, according to the literature, the recurrence 
rate varies as per the criteria used for diagnosis: clinical, endo-
scopic, radiological, or surgical.
The term recurrence refers to the appearance of lesions after 
surgery, which is evaluated using imaging methods (as ultra-
sound, computed tomography, or magnetic resonance imag-
ing) or using endoscopy (7). Currently, ileocolonoscopy is the 
first-line method for diagnosing postoperative ER and is recom-
mended to be performed during the first year after surgery (7). 
Our analysis evaluated ER after and between 6-12 months of 
surgery according to the Rutgeerts´ score and compared the 
risk factors between groups with ER and without ER. After ileo-
colic resection, we observed an ER of 59.5% after a mean of 9 
months.
There was no statistical difference regarding sex and age at sur-
gery between the groups with ER and without ER. Actually, sex 
has not been proven to be a risk factor for ER (7,8). Additionally, 
there is conflicting evidence regarding the effect of age on the 
risk for ER; therefore, it is not a definite risk factor for ER (7,9,10).
Although we did not find a statistically significant difference in 
ER between the groups of smokers and nonsmokers probably 
because we had few smoker patients, most studies showed 
that it is a modifiable patient-related independent predictor 
(10-13).
As per the Montreal classification, none of the parameters 
showed a statistical difference relative to ER. Although in this 
study, the behavior of the disease according to the Montreal 
classification has not been shown to be a predictor of ER, the 
majority of our patients had a penetrating phenotype, and 
this has been consistently known to be a risk factor for an ag-
gressive disease course and a predictor of ER in the literature 
(14-16).
In this study, the presence of perianal disease increased the risk 
for ER. It is well known that patients with a perianal disease are 
a subgroup of patients with a more severe disease, which has 
been associated to an increased risk for ER (2,17).
A shorter duration of CD in the ER group was found, with a 
statistical difference from the non-ER group, and has been es-
tablished as a risk factor in our study. However, there is conflict-
ing data regarding the association of the disease duration with 
the risk for ER (9). Several studies have shown the association 
between ER and the duration of the disease. Pogglioli et al. (18) 
found a higher incidence of ER in patients with disease dura-
tion of <6 years compared with patients with a duration of CD 
of >6 years. In contrast, Lautenbach et al. (19) found an associa-
tion between the longer duration of disease and surgery.
The majority of patients had a perforating indication for surgery. 
We found no significant difference in ER between perforating 
and non-perforating indications. The role of surgical indication 
in CD recurrence remains controversial, with some studies sug-
gesting that perforating CD results in a higher recurrence rate 
compared with non-perforating CD, whereas other studies 
have not shown a difference in recurrence (6,20-22). 
In our series, there was no association between the extension 
of the surgical resection specimen and ER maybe because we 
did not have any case of extensive resection. Several stud-
ies have demonstrated that recurrence is higher after a long 
length resection of the diseased bowel (2). However, other 
studies have not shown this association (23).
There are contradictory reports about granulomas in the resec-
tion specimen on recurrence (16,24-26). In a recent report, the 
presence of granulomas in the mesenteric lymph nodes was 
found to be an independent risk factor for ER (27).
Several medications, such as mesalamine or antibiotics, have 
been advocated for the prevention of postoperative disease 
recurrence (28,29). However, the marginal role of mesalamine 
for preventing ER is currently known and with regard to met-
ronidazole, loss of efficacy beyond 12 months and side effects 
precludes its use in the prevention of ER (7,29,30).
Thiopurines have been shown to reduce endoscopic and clini-
cal recurrence postoperatively (31). Recent reports suggest 
that anti-TNF drugs, infliximab, and adalimumab can delay and 
reduce postoperative recurrence (32,33).
Statistically, postoperative medication (thiopurines or anti-TFN 
drugs) did not affect the rate of ER. This might be due to the 
fact that only 11 patients (26.2%) had not taken thiopurines 
and only 11 patients (26.2%) have been treated with anti-TNF 
drugs post-surgery. However, we can raise the hypothesis that 
the high number of our patients who maintained thiopurines 
post-surgery can decrease the ER rate because our rate of ER 
(59.5%) is lower than the Rutgeerts reports (3,4).
The optimal monitoring and prophylaxis strategy for postop-
erative recurrence has not been established. Some authors 
recommend prophylaxis with thiopurines, soon after surgery, 
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in high-risk patients (34). De Cruz et al. (35) recently reported 
that treatment, according to recurrence risk, and adjusting it on 
the basis of ileocolonoscopy findings at 6 months after surgery 
is better than conventional drug therapy alone for preventing 
postoperative CD recurrence. 
There are several limitations to our study because it is a ret-
rospective study design that reviews medical records and the 
number of included patients in each group may preclude a 
significant p value.
Nevertheless, our study revealed that almost two-thirds of CD 
patients had ER. Most of these had a severe ER (≥i3), with im-
portant implications for prognosis, with perianal involvement, 
and a shorter duration of disease, being significant risk factors. 
Therefore, identification of patients at high risk for ER allows a 
targeted approach of these patients, benefiting from increased 
monitoring and therapeutic prophylaxis and hoping for a bet-
ter prognosis for these patients.
Further studies designed to analyze the impact of immediate 
prophylaxis after surgery in identified high-risk patients is war-
ranted to find the best practice for these patients.
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